Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma
Open Access
- 1 February 2020
- journal article
- research article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 124 (2) , 190-196
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharmaceuticals Corporation
- Genentech
This publication has 36 references indexed in Scilit:
- Step-up Therapy for Children with Uncontrolled Asthma Receiving Inhaled CorticosteroidsNew England Journal of Medicine, 2010
- Total IgE levels and asthma prevalence in the US population: Results from the National Health and Nutrition Examination Survey 2005-2006Journal of Allergy and Clinical Immunology, 2009
- Lung function decline in asthmaEuropean Respiratory Journal, 2007
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLARAllergy, 2004
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthmaAllergy, 2004
- Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaClinical & Experimental Allergy, 2004
- Usefulness of monitoring lung function in asthmaArchives of Disease in Childhood, 2003
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- What are minimal important changes for asthma measures in a clinical trial?European Respiratory Journal, 1999
- Blood eosinophils and eosinophil-derived proteins in allergic asthmaJournal of Allergy and Clinical Immunology, 1989